FDA Approves GSK's Hibsago for Noncirrhotic Adults With Chronic Hepatitis B

The supplied context explicitly identifies an FDA approval on October 20, 2026 for GSK's Hibsago (bepirovirsen) in certain adults with chronic hepatitis B without cirrhosis. This is a material, forward-looking regulatory milestone that enables U.S. commercialization of a first-in-class therapy and has direct implications for GSK, partnered-asset economics for Ionis, and Roche's authorized companion diagnostic. The approval was somewhat anticipated because the FDA's PDUFA target date was October 26, 2026, so the surprise score is moderate rather than high. Gilead and Bristol Myers Squibb are approved as affected incumbent CHB antiviral companies because the supplied trial context states that some Hibsago recipients met criteria to discontinue existing therapy; pipeline competitors are excluded because their effects are more speculative. The date is explicit, but the actual FDA decision time is not provided, so the timestamp is normalized to midnight UTC and given lower timestamp confidence. This development is not a duplicate of the prior Japan approval and clearly continues the existing Hibsago regulatory-approval and commercialization storyline represented by event 2454.